Herceptin

Latest articles

1d
Business Wire
Samsung Bioepis es la primera empresa en obtener una opinión favorable del CHMP sobre un producto biosimilar de trastuzumab, ONTRUZANT®Europea de Medicamentos (EMA), ha dado una opinión positiva con respecto al can
Business Wire / Posted yesterday
Europea de Medicamentos (EMA), ha dado una opinión positiva con respecto al candidato de producto ONTRUZANT® biosimilar de Herceptin ® (trastuzumab), para el tratamiento del cáncer de mama en fase inicial, del cáncer de mama metastático y del... Read more
487 related articles
3d
Channel NewsAsia
Biosimilar cancer drug threat closing in for RocheRoche, the world's biggest maker of oncology treatments. Last Friday's green l
Channel NewsAsia / Posted 3 days ago
Roche, the world's biggest maker of oncology treatments. Last Friday's green light for a copy of its breast cancer drug Herceptin heralds the arrival of the second so-called cancer biosimilar in Europe this year, following the launch six months... Read more
6d
Business Wire
Samsung Bioepis erhält zustimmende Bewertung vom CHMP für Trastuzumab-Biosimilar mit ONTRUZANT®Agency, EMA) eine zustimmende Bewertung für ONTRUZANT® abgegeben hat, einem Bio
Business Wire / Posted 6 days ago
Agency, EMA) eine zustimmende Bewertung für ONTRUZANT® abgegeben hat, einem Biosimilar-Kandidaten mit Bezugnahme auf Herceptin® (Trastuzumab) zur Behandlung von Brustkrebs im Frühstadium, metastatischem Brustkrebs und metastatischem... Read more
623 related articles
6d
Business Wire
Samsung Bioepis riceve per prima, con ONTRUZANT®, un parere positivo da parte del CHMP su un biosimilare di trastuzumabeuropea del farmaco (European Medicines Agency, EMA) ha espresso un parere posi
Business Wire / Posted 6 days ago
europea del farmaco (European Medicines Agency, EMA) ha espresso un parere positivo su ONTRUZANT®, candidato biosimilare di Herceptin® (trastuzumab), per il trattamento di cancro mammario iniziale, cancro mammario metastatico e cancro gastrico... Read more
109 related articles
6d
Business Wire
Samsung Bioepis verkrijgt met ONTRUZANT® als eerste positief oordeel van CHMP voor een biosimilair van Trastuzumabgebruik van het Europees Geneesmiddelenbureau (EMA) positief heeft geoordeeld o
Business Wire / Posted 6 days ago
gebruik van het Europees Geneesmiddelenbureau (EMA) positief heeft geoordeeld over ONTRUZANT®, een biosimilair van Herceptin® (trastuzumab) voor de behandeling van vroege borstkanker, uitgezaaide borstkanker en uitgezaaide maagkanker. Het... Read more
68 related articles
7d
Daily Record
Brave Airdrie breast cancer mum to participate in special Hilton fashion showHilton Hotel, Glasgow. Kirsteen, a personal assistant, has undergone a lengthy
Daily Record / Posted 7 days ago
Hilton Hotel, Glasgow. Kirsteen, a personal assistant, has undergone a lengthy treatment of chemotherapy, radiotherapy and Herceptin and cannot wait to take part. The 45-year-old said: “I was stunned at being diagnosed with breast cancer in May... Read more
10d
Channel NewsAsia
Roche shares hit by trial flops, fears over biosimilar defensebusiness as rivals produce cheaper biosimilar copies of its biggest sellers - t
Channel NewsAsia / Posted 10 days ago
business as rivals produce cheaper biosimilar copies of its biggest sellers - the US$20 billion-a-year trio of cancer drugs Herceptin, Avastin and Rituxan. But the recent flops, coupled with disappointing results this year on its immunotherapy... Read more
11d
Business Wire
Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congresscomparative safety and efficacy study of the company’s investigational trastuzu
Business Wire / Posted 11 days ago
comparative safety and efficacy study of the company’s investigational trastuzumab biosimilar (PF-05280014) versus Herceptin®1 (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid. Positive data from a... Read more
13d
Channel NewsAsia
Roche eye drug fails late-stage trial in blow to pipelinehopes of offsetting the impact of cheaper copies of its biggest sellers - the U
Channel NewsAsia / Posted 13 days ago
hopes of offsetting the impact of cheaper copies of its biggest sellers - the US$20-billion-per-year trio of cancer drugs Herceptin, Avastin and Rituxan - that are starting to hit the market. Its failure in tests is the latest in a string of... Read more
13d
Business Wire
Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congressa double-blind, placebo-controlled, Phase III trial of neratinib versus placebo
Business Wire / Posted 13 days ago
a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in patients with early stage HER2-positive breast cancer. The predefined 5-year invasive disease free survival... Read more
15d
Business Wire
BizVibe Examines the Top Products and Companies in the Global Oncology Drug Marketof more than USD 4 billion last year and is projected to generate sales of over
Business Wire / Posted 15 days ago
of more than USD 4 billion last year and is projected to generate sales of over USD 13 billion in the next five years. 3. Herceptin: As another of Roche’s blockbuster drugs, Herceptin is used for the treatment of HER2+ breast cancer. Sales of... Read more
16d
The New Yorker
Cancer’s Invasion Equationis also grateful for the kind of genetic tests that indicate which patients mig
The New Yorker / Posted 16 days ago
is also grateful for the kind of genetic tests that indicate which patients might benefit from a targeted therapy like Herceptin (those whose breast cancers produce high levels of the growth-factor receptor protein HER2) or from anti-estrogen... Read more
21d
Business Wire
Puma Biotechnology Announces Publication of Abstracts for ESMO 2017a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo
Business Wire / Posted 21 days ago
a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer. U.S. Approval of Neratinib (NERLYNX™) Neratinib was... Read more
30d
Geelong Advertiser
Staring down cancer with aplombhad finished and a scan showed that the liver lesions had responded to treatmen
Geelong Advertiser / Posted 30 days ago
had finished and a scan showed that the liver lesions had responded to treatment and reduced in size. Instead Julia had Herceptin drips every three weeks in the oncology ward at the hospital and gradually the side effects of the toxic chemo... Read more
1m
Arkansas Democrat-Gazette
Insurers' pacts set barriers to drugsin coming years, including competitors for top-selling cancer drugs such as Amg
Arkansas Democrat-Gazette / Posted a month ago
in coming years, including competitors for top-selling cancer drugs such as Amgen's bevacizumab, marketed as Avastin by Genentech, now a unit of Roche Holding, and Mylan's version of Herceptin from Genentech. SundayMonday Business on 0... Read more
1m
The Star
Samsung Bioepis teams up with Takeda to develop original biotech drugsJohnson's Remicade, and awaits European regulatory decisions for its biosimilar
The Star / Posted a month ago
Johnson's Remicade, and awaits European regulatory decisions for its biosimilar versions of AbbVie Inc's Humira and Roche's Herceptin. [nL3N1KF4OL][nL4N1A40FZ][nL4N1A40FZ] Samsung Bioepis will also seek partnerships with other drugmakers to become... Read more
2 related articles
1m
Channel NewsAsia
Samsung Bioepis teams up with Takeda to develop original biotech drugsJohnson's Remicade, and awaits European regulatory decisions for its biosimilar
Channel NewsAsia / Posted a month ago
Johnson's Remicade, and awaits European regulatory decisions for its biosimilar versions of AbbVie Inc's Humira and Roche's Herceptin. Samsung Bioepis will also seek partnerships with other drugmakers to become an original drugmaker that can... Read more
2 related articles
m
Morningstar
Promise in New Cancer Treatments, for Patients and Investorsin the investment community that the biosimilars will take a lot of market shar
Morningstar / Posted 1 months ago
in the investment community that the biosimilars will take a lot of market share from Roche’s older biologics, drugs like Herceptin and Rituxan. We also think the biosimilars are going to take some market share. But we think people are... Read more

In this news